Synfacts, Table of Contents Synfacts 2023; 19(06): 0619DOI: 10.1055/s-0042-1752686 Innovative Drug Discovery and Development A PhI CXCR3 Antagonist Making Progress in its Clinical Development for Inflammatory Disorders Contributor(s): Antonia F. Stepan (Roche) , Erika A. Crane (Drug Hunter, Inc.) Recommend Article Abstract Buy Article Key words Key wordsCXCR3 - CYP2D6 - inflammation - clinical candidate Full Text